Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

LBA-005VELOUR trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.

Wirapati P, Pomella V, Vandenbosch B, Kerr P, Maiello E, Jeffery Grahame M, Razvan-Ovidiu D C, Karthaus M, John A B, Anca C M, Kiss I, Merino S, McKendrick Joseph J, Saridaki Z, Xavier Ja S, Tejpar S.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302.004. No abstract available.

PMID:
30052787
2.

Colchicum Genus in the Writings of Ancient Greek and Byzantine Physicians.

Tsoucalas G, Papaioannou T, Panayiotakopoulos G, Saridaki Z, Vrachatis DA, Karamanou M.

Curr Pharm Des. 2018;24(6):648-653. doi: 10.2174/1381612824666180115111546.

PMID:
29336250
3.

Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.

Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulias V, Souglakos J.

Pharmacogenomics J. 2017 Dec;17(6):506-514. doi: 10.1038/tpj.2016.63. Epub 2016 Oct 25.

PMID:
27779244
4.

Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.

Yan P, Klingbiel D, Saridaki Z, Ceppa P, Curto M, McKee TA, Roth A, Tejpar S, Delorenzi M, Bosman FT, Fiocca R.

Clin Cancer Res. 2016 Jun 15;22(12):3037-47. doi: 10.1158/1078-0432.CCR-15-0939. Epub 2016 Feb 9.

5.

Avenzoar's (1091-1162) clinical description of cancer.

Karamanou M, Tsoucalas G, Saridaki Z, Iavazzo C, Androutsos G.

J BUON. 2015 Jul-Aug;20(4):1171-4.

PMID:
26416074
6.

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?

Saridaki Z, Saegart X, De Vriendt V, Hatzidaki D, Palmans S, De Smedt L, De Hertogh G, Tejpar S.

Br J Cancer. 2015 Sep 15;113(6):914-20. doi: 10.1038/bjc.2015.307. Epub 2015 Sep 1.

7.

René-Théophile-Hyacinthe Laennec (1781-1826) and the description of metastatic pulmonary melanoma.

Karamanou M, Stratigos AJ, Saridaki Z, Tsoucalas G, Androutsos G.

J BUON. 2015 Jan-Feb;20(1):354-6.

PMID:
25778343
8.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2015 Jan;26(1):126-32. doi: 10.1093/annonc/mdu499. Epub 2014 Oct 30.

PMID:
25361982
9.

Cost-Effectiveness Analysis of Panitumumab+Mfolfox over Bevacizumab+Mfolfox as a First-Line Treatment for Metastatic Colorectal Cancer Patients with Wild-Type Ras in Greece.

Kourlaba G, Boukovinas I, Saridaki Z, Papagiannopoulou V, Tritaki G, Maniadakis N.

Value Health. 2014 Nov;17(7):A633. doi: 10.1016/j.jval.2014.08.2268. Epub 2014 Oct 26. No abstract available.

10.

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S.

Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348.

11.

Prognostic and predictive significance of MSI in stages II/III colon cancer.

Saridaki Z, Souglakos J, Georgoulias V.

World J Gastroenterol. 2014 Jun 14;20(22):6809-14. doi: 10.3748/wjg.v20.i22.6809. Review.

12.

ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples.

Kalogeraki A, Karvela-Kalogeraki I, Tamiolakis D, Petraki P, Saridaki Z, Tzardi M.

Rev Port Pneumol. 2014 Jul-Aug;20(4):200-7. doi: 10.1016/j.rppneu.2013.11.002. Epub 2014 Feb 6.

13.

BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.

Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J.

PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013.

14.

The eminent dermatologist Moriz Kaposi (1837-1902) and the first description of idiopathic multiple pigmented sarcoma of the skin.

Karamanou M, Antoniou C, Stratigos AJ, Saridaki Z, Androutsos G.

J BUON. 2013 Oct-Dec;18(4):1101-5.

PMID:
24344048
15.

The great surgeon Jean-Louis Faure (1863-1944) and his contribution in the treatment of uterine cancer.

Karamanou M, Saridaki Z, Piagkou M, Laios K, Androutsos G.

J BUON. 2013 Jan-Mar;18(1):296-8.

PMID:
23613423
16.

Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.

Saridaki Z, Lambrodimou G, Kachris S, Makrantonakis P, Boukovinas I, Polyzos A, Anagnostopoulos A, Athanasiadis A, Stoltidis D, Georgoulias V, Souglakos J.

Am J Clin Oncol. 2015 Feb;38(1):17-22. doi: 10.1097/COC.0b013e3182893f13.

PMID:
23563209
17.

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.

Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J.

Br J Cancer. 2012 Dec 4;107(12):1932-7. doi: 10.1038/bjc.2012.509. Epub 2012 Nov 20.

18.

Cytopathologic interpretation of ascites due to malignancy.

Kalogeraki A, Karvela-Kalogeraki I, Tamiolakis D, Petraki P, Papathanasiou A, Saridaki Z, Stathopoulos EN, Tzardi M.

J BUON. 2012 Jul-Sep;17(3):446-51. Review.

PMID:
23033279
19.

Aretaeus of Cappadocia and the first description of diabetes.

Laios K, Karamanou M, Saridaki Z, Androutsos G.

Hormones (Athens). 2012 Jan-Mar;11(1):109-13.

20.

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.

Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulias V, Mavroudis D.

J BUON. 2011 Apr-Jun;16(2):215-8.

PMID:
21766488

Supplemental Content

Loading ...
Support Center